Navigation Links
Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report first quarter 2011 financial results on Thursday, May 5, 2011, after the U.S. financial markets close.

Anadys will hold a conference call and webcast on Thursday, May 5, 2011 at 5:00 p.m. Eastern Daylight Time to discuss its first quarter 2011 financial results and highlights and to provide an update on its development programs.  A live webcast of the call will be available online at www.anadyspharma.com.  A telephone replay will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 23621944.  The webcast and telephone replay will be available through May 19, 2011.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is conducting a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2010.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
2. Anadys Pharmaceuticals Augments Management Team and Board of Directors
3. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
4. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
5. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
6. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
7. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
8. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
9. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
10. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
11. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: ... personalized immune therapies for operable and inoperable solid tumor ... Chief Technical Officer of NW Bio, will present at ... 2017, at the Hyatt Regency Hotel in ... chair the session entitled "New Therapeutic Approaches – Expanding ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, ... into a compact business-card sized form factor suitable for prototyping, testing, and production-ready ...
(Date:1/18/2017)... 18, 2017 Applied BioMath ( www.appliedbiomath.com ... drug research and development, today announced that Dr. ... CEO of Applied BioMath, will present at the ... (BAGIM) Meeting on Thursday January 19, 2017 at ... , MA.   Dr. Burke,s talk "Quantitative Modeling and ...
(Date:1/18/2017)... MA (PRWEB) , ... January 18, 2017 , ... ... today that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took ... Center in Valley Stream, NY. The procedure was an anterior cervical discectomy and ...
Breaking Biology Technology:
(Date:1/19/2017)... CLARA, Calif. , Jan. 19, 2017 /PRNewswire/ ... company enhancing user experience and security for consumer ... of next-generation payment processing systems and cybersecurity solutions, ... more banks, enterprises and financial institutions worldwide to ... part of the end-to-end secure user authentication platforms ...
(Date:1/13/2017)... PORT WASHINGTON, N.Y. , Jan. 13, 2017 ... provider of technology solutions for the homecare industry, ... appointment of homecare industry expert, Justin Jugs, as ... Justin brings more than 15 years of homecare ... the team in developing strategic plans to align ...
(Date:1/12/2017)... 2017 A new report by Allied Market Research, titled, "Global ... technology market is expected to generate revenue of $10.72 billion by 2022, with an ... Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the year ...
Breaking Biology News(10 mins):